Vision of Sustainability
Following its core business values of “Integrity, Innovation, and Love”, Oneness Biotech establishes alliance with integrity, expands to new market with innovation, and gives feedback to the society with love. We will continue increasing our strength in research and development in order to develop world-class innovative drugs and help create a healthy life for the humankind. We will integrate sustainability strategies into business operation and development, carry out our corporate social responsibilities, and protect a sustainable environment for future generations.
Sustainable Management Structure
Stakeholders used to focus on that pharmaceutical industry's economic value as corporate profits and the social value as improvement of the health and welfare of human beings. However, with the development of triple-bottom-line business models, which have not only economic and social, but also environmental, considerations, stakeholders have paid more and attention to the environmental value of the pharmaceutical industry.
In order to promote the Company’s sustainable operation and ensure that relevant risks and opportunities are effectively governed, the Company has established a comprehensive and systematic management mechanism covering the three levels of governance decision-making, supervision management, and promotion implementation, thereby ensuring close integration between of the sustainable strategies and risk management.
The Board of Directors acts as the highest decision-making and supervisory unit for the Company’s sustainable development, and it is responsible for reviewing sustainability-related policies, goals, and material issues. It regularly tracks implementation status, in order to ensure that the sustainable development direction aligns with the Company’s overall operating strategies.
The Risk Management Committee convenes at least two meetings annually. The Sustainability and Risk Implementation Committee reports the major risks identified for the current year, the responsible unit, and risk control measures during the first quarter of each year, and also reviews the implementation results of risk control during the fourth quarter. Meetings were held on February 29 and November 11, 2024, respectively.
※The above content is taken from the ESG Report
